<DOC>
	<DOCNO>NCT00624182</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immune response different dos URLC10 peptide emulsify Montanide ISA51 combination gemcitabine . Recommended phase II dose also determine .</brief_summary>
	<brief_title>Gemcitabine With Peptide Vaccine Therapy Treating Patients With Bile Duct Cancer</brief_title>
	<detailed_description>Our previous study demonstrate up-regulated lung cancer 10 ( URLC10 ) identify new target tumor associate antigen use cDNA microarray technique combine expression profile normal cancer tissue . We also find 100 % tissue sample bile duct cancer express URLC10 . We determine HLA-A*2402 HLA-A*0201 restrict epitope peptide derive URLC10.These epitope peptide show induce specific Cytotoxic T Lymphocytes ( CTL ) . Furthermore , 60 % 20 % Japanese population HLA-A*2402 HLA-A*0201 , respectively . Therefore , peptide suitable clinical trial . On hand , gemcitabine drug approve bile duct cancer . Recent study report gemcitabine additional ability improve immune response . From result , synergistic effect vaccine therapy chemotherapy use gemcitabine expect . In clinical trial , evaluate safety , tolerability , immune response different dos URLC10 peptide emulsify Montanide ISA51 immunochemotherapy patient unresectable recurrent bile duct cancer . Toxicity profile monitor , antigen specific T cell response describe .</detailed_description>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1 . Advanced bile duct cancer preclude curative surgical resection recurrent bile duct cancer 2. measurable disease CT scan , ultrasonography , image modality . PATIENTS CHARACTERISTICS 1 . ECOG performance status 02 2 . Life expectancy &gt; 3 month 3 . Laboratory value follow 2,000/mm³ &lt; WBC &lt; 15,000/mm³ Platelet count ≥ 75,000/mm³ Bilirubin ≤ 1.5 x institutional normal upper limit AST , ALT , ALP ≤ 2.5 x institutional normal upper limit Creatinine ≤ 1.5 x institutional normal upper limit 4 . HLAA*2402 HLAA*0201 5 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Serious uncontrolled infection 4 . Prior chemotherapy ( except gemcitabine ) , radiation therapy , immunotherapy within 4 week . 5 . Other malignancy within 5 year prior entry study 6 . Concomitant treatment steroid immunosuppressing agent 7 . Disease central nervous system 8 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>